TriSalus Life Sciences
TLSI
30 hedge funds and large institutions have $12.4M invested in TriSalus Life Sciences in 2024 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 6 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
23% more capital invested
Capital invested by funds: $10M → $12.4M (+$2.35M)
0.68% more ownership
Funds ownership: 7.41% → 8.09% (+0.68%)
6% less funds holding
Funds holding: 32 → 30 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$753K |
| 2 |
GL
Graypoint LLC
Albany,
New York
|
+$509K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$254K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$211K |
| 5 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Exos Asset Management
New York
|
-$148K |
| 2 |
VF
Virtu Financial
New York
|
-$92K |
| 3 |
Lido Advisors
Los Angeles,
California
|
-$88.7K |
| 4 |
Millennium Management
New York
|
-$73.3K |
| 5 |
HF
HRT Financial
New York
|
-$71K |
TLSI Hedge Fund Activity: Q4 2024 in Review
30 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q4 2024, worth a combined $12.4M — up 23% from $10M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TLSI and 4 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Bank of America, adding an estimated $753K. The largest seller was Exos Asset Management, cutting an estimated $148K.
- 30 institutional investors held TriSalus Life Sciences (TLSI) as of Q4 2024, down from 32 in Q3 2024.
- Funds reported $12.4M of TriSalus Life Sciences stock for Q4 2024, up 23% quarter-over-quarter.
- 4 funds opened new TriSalus Life Sciences positions in Q4 2024 and 6 closed out, a net change of -2 holders.
- The largest TriSalus Life Sciences buyer in Q4 2024 was Bank of America, an estimated $753K added.
- The largest TriSalus Life Sciences seller in Q4 2024 was Exos Asset Management, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2024.